Journal of Intellectual Property Rights

Open Access Open Access  Restricted Access Subscription Access

Judicial Navigation of Drug Name Regulation in India


Affiliations
1 Rajiv Gandhi School of Intellectual Property Law Indian Institute of Technology Kharagpur, Kharagpur – 721302,West Bengal,, India

Almost two decades back the Supreme Court of India while deciding the trademark disputes related to pharmaceutical products raised serious concerns towards the medicines sold under unregulated similar proprietary names. Thereby the judiciary issued directions to the drug regulatory authority for drug name regulation. However, since then in the absence of a definite regulatory structure, the judiciary has continued navigating the scope of India’s drug name regulation. In this context, the article reflects upon the judicial attempts for integrating drug-name regulations in the current regulatory structure, while critically analyzing the judiciary-backed recent amendments in the Drugs and Cosmetics Rule, 1945.
User
Notifications
Font Size

Abstract Views: 89




  • Judicial Navigation of Drug Name Regulation in India

Abstract Views: 89  | 

Authors

Kuhu Tiwari
Rajiv Gandhi School of Intellectual Property Law Indian Institute of Technology Kharagpur, Kharagpur – 721302,West Bengal,, India
Niharika Sahoo Bhattacharya
Rajiv Gandhi School of Intellectual Property Law Indian Institute of Technology Kharagpur, Kharagpur – 721302,West Bengal,, India

Abstract


Almost two decades back the Supreme Court of India while deciding the trademark disputes related to pharmaceutical products raised serious concerns towards the medicines sold under unregulated similar proprietary names. Thereby the judiciary issued directions to the drug regulatory authority for drug name regulation. However, since then in the absence of a definite regulatory structure, the judiciary has continued navigating the scope of India’s drug name regulation. In this context, the article reflects upon the judicial attempts for integrating drug-name regulations in the current regulatory structure, while critically analyzing the judiciary-backed recent amendments in the Drugs and Cosmetics Rule, 1945.